Autism Speaks   Report issue

Foundation Phase 1 Phase 2 Phase 3
Founded: New York NY United States (2005)

Organization Overview

First Clinical Trial
2007
NCT00773812
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Autism Speaks

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aggression (Phase 1)

Autism Spectrum Disorder (Phase 3)

Autistic Disorder (Phase 3)

Child Development Disorders, Pervasive (Phase 3)

Developmental Disabilities (Phase 3)

Disease (Phase 3)

Fragile X Syndrome (Phase 2)

Language Disorders (Phase 2)

Rett Syndrome (Phase 1)

Sclerosis (Phase 2)

Syndrome (Phase 2)

Tuberous Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 13